18F-FAPI与18F-FDG PET/CT评估溃疡性结肠炎肠道病变及疾病活动度的对比分析
该前瞻性队列研究纳入23例新诊断或复发溃疡性结肠炎患者,评估113个肠段(含90个病变肠段),在1周内完成18F-FAPI PET/CT、18F-FDG PET/CT、腹部增强CT及结肠镜检查,以MES为参考标准。结果显示18F-FAPI PET/CT在检测肠道病变和评估疾病活动度方面均显著优于18F-FDG PET/CT,且与内镜、增强CT、临床表现及生物标志物相关性良好。
要点
- 18F-FAPI PET/CT检测肠道病变优于18F-FDG PET/CT(P=0.046)和腹部增强CT(P=0.007)。
- FAPI-TBR与MES(R2=0.75)及增强CT评分(R2=0.55)的相关性均强于FDG-TBR。
- 18F-FAPI PET/CT在肠段和患者水平区分不同疾病活动度均更优(P<0.001;P<0.05)。
核心结论
- 18F-FAPI PET/CT评估溃疡性结肠炎肠道病变和疾病活动度的效能优于18F-FDG PET/CT。
- 18F-FAPI PET/CT与内镜、腹部增强CT、临床表现及生物标志物相关性良好,有望成为无创评估疾病活动度的方法。
研究设计与样本
- 前瞻性队列研究,纳入新诊断或复发溃疡性结肠炎患者23例。
- 所有参与者1周内完成18F-FAPI PET/CT、18F-FDG PET/CT、腹部增强CT和结肠镜检查。
- 以Mayo内镜评分(MES)为肠道病变识别和严重度评估的参考标准,共评估113个肠段(含90个病变肠段)。
主要发现
- ROC分析显示18F-FAPI PET/CT检测肠道病变显著优于18F-FDG PET/CT(P=0.046)和腹部增强CT(P=0.007)。
- FAPI-TBR与MES(R2=0.75)及腹部增强CT评分(R2=0.55)的相关性强于FDG-TBR。
- 18F-FAPI PET/CT在肠段水平(P<0.001)和患者水平(P<0.05)区分不同疾病活动度均更优。
- 全局18F-FAPI PET/CT评分与其他活动度指标显著相关(r=0.49-0.76)。
- ROC分析显示18F-FAPI PET/CT检测活动性病变显著优于18F-FDG PET/CT(P<0.001)和腹部增强CT(P=0.001)。
关键数值与推荐
- 以MES作为肠道病变识别和严重度评估的参考标准。
- 计算各肠段18F-FAPI/18F-FDG PET/CT的靶本比(TBR)及全局18F-FAPI/18F-FDG PET/CT评分。
- 检查前计算部分Mayo评分,并测定C反应蛋白、白细胞介素-6、红细胞沉降率、血小板和血红蛋白水平。
临床怎么用
- 18F-FAPI PET/CT可作为无创评估溃疡性结肠炎疾病活动度的有前景方法。
- 在检测肠道病变和活动性病变方面,18F-FAPI PET/CT优于18F-FDG PET/CT和腹部增强CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate evaluation of intestinal lesions and severity assessment of ulcerative colitis (UC) are crucial for therapeutic strategies and prognosis. This study aims to compare the efficacy of 18 F-FAPI and 18 F-FDG PET/CT in the evaluation of intestinal lesions and disease activity assessment of UC. METHODS: This is a prospective cohort study, and patients with newly diagnosed or relapsed UC were enrolled. All participants underwent 18 F-FAPI PET/CT, 18 F-FDG PET/CT, abdominal contrast-enhanced CT, and colonoscopy within 1 week. Mayo Endoscopic Subscore (MES) was used as the reference standard for identification and severity assessment of intestinal lesions. Target-to-background ratio (TBR) of each segment in 18 F-FAPI/ 18 F-FDG PET/CT and global 18 F-FAPI/ 18 F-FDG PET/CT score were computed to represent the activity of independent segments and all segments, respectively. Before examinations, partial Mayo score was calculated based on clinical manifestations of patients, and levels of C-reactive protein, interleukin-6, erythrocyte sedimentation rate, platelet, and hemoglobin were determined. Finally, all data were analyzed to compare the efficacy of 18 F-FAPI and 18 F-FDG PET/CT in the evaluation of intestinal lesions and disease activity in UC. RESULTS: A total of 113 intestinal segments (including 90 lesion segments) were evaluated among 23 participants. Through receiver operating characteristic (ROC) analysis, 18 F-FAPI PET/CT showed significantly superior performance in detecting intestinal lesions compared with 18 F-FDG PET/CT ( P = 0.046) and abdominal contrast-enhanced CT ( P = 0.007). The correlations between FAPI-TBR and MES ( R2 = 0.75) and abdominal contrast-enhanced CT score ( R2 = 0.55) were stronger than those of FDG-TBR. 18 F-FAPI PET/CT showed superior discriminative capacity across different disease activity levels at both segmental ( P < 0.001) and patient-level ( P < 0.05) in intergroup comparison. The global 18 F-FAPI PET/CT score was significantly correlated with other activity indicators ( r = 0.49-0.76). Moreover, 18 F-FAPI PET/CT was also significantly superior to 18 F-FDG PET/CT ( P < 0.001) and abdominal contrast-enhanced CT ( P = 0.001) in detecting active lesions according to ROC analysis. CONCLUSIONS: The efficacy of 18 F-FAPI PET/CT in the evaluation of intestinal lesions and disease activity assessment of UC was superior to that of 18 F-FDG PET/CT. 18 F-FAPI PET/CT also correlated well with endoscopy, abdominal contrast-enhanced CT, clinical manifestations, and biomarkers. Therefore, 18 F-FAPI PET/CT may be a promising method for noninvasive assessment of disease activity of UC.
引用
- Li W, Shi W, Li X, et al. Comparative Analysis of 18 F-FAPI and 18 F-FDG PET/CT in Evaluation of Intestinal Lesions and Disease Activity in Ulcerative Colitis. Clin Nucl Med. 2026. PMID: 41718603. doi:10.1097/RLU.0000000000006371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。